Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06315491
Status:
RECRUITING
Last Update Posted:
2024-03-18
First Post:
2024-03-07
Brief Title:
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Sponsor:
Cybrexa Therapeutics
Organization:
Cybrexa Therapeutics
Study Overview
Official Title:
A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety tolerability and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses 125 mgm2 every 21 days or 100 mgm2 every 21 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None